News
OPT
4.110
+5.12%
0.200
Weekly Report: what happened at OPT last week (0318-0322)?
Weekly Report · 4d ago
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
Opthea Limited will host a virtual key opinion leader event on April 3, 2024, featuring presentations from global retina experts. Opthea is a clinical-stage biopharmaceutical company developing novel therapies to treat retinal diseases. The event will take place in Melbourne, Australia.
Barchart · 03/19 05:00
Weekly Report: what happened at OPT last week (0311-0315)?
Weekly Report · 03/18 09:24
Weekly Report: what happened at OPT last week (0304-0308)?
Weekly Report · 03/11 09:24
Tracking Baker Brothers Portfolio - Q4 2023 Update
Seeking Alpha · 03/06 22:09
Opthea to Participate in the Leerink Partners Global Biopharma Conference
Opthea Limited is a clinical-stage biopharmaceutical company developing novel therapies to treat retinal diseases. Management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference in Miami, Florida on March 11-13, 2024.
Barchart · 03/05 16:08
Weekly Report: what happened at OPT last week (0226-0301)?
Weekly Report · 03/04 09:24
Buy Rating for Opthea Limited on Promising Phase 2b Results of Sozinibercept for Wet AMD
Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on the stock and has a $14.00 price target. Opthea Limited Sponsored ADR's lead asset, sozinibercept, is being developed to treat wet age-related macular degeneration.
TipRanks · 02/29 11:28
Opthea reports 2H results
Opthea reports 2H results Feb. 29, 2024. Net Cash Flows Used in Operating Activities for the six months ended December 31, 2023 ended at $69.4 million. The company had $157.1 million in cash and cash equivalents as of Dec. 31, 2022.
Seeking Alpha · 02/29 07:52
Opthea Reports Half-Year Financial Results and Business Updates
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025. Expanded U.S. Leadership team with the appointments of Dr. Frederic Guerard as CEO.
Barchart · 02/28 16:55
Weekly Report: what happened at OPT last week (0219-0223)?
Weekly Report · 02/26 09:26
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Opthea Limited appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist. Opthea is a clinical-stage biopharmaceutical company developing novel therapies to treat retinal diseases.
Barchart · 02/19 17:25
Weekly Report: what happened at OPT last week (0212-0216)?
Weekly Report · 02/19 09:27
Weekly Report: what happened at OPT last week (0205-0209)?
Weekly Report · 02/12 09:24
Weekly Report: what happened at OPT last week (0129-0202)?
Weekly Report · 02/05 09:26
Weekly Report: what happened at OPT last week (0122-0126)?
Weekly Report · 01/29 09:24
Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Netflix shares jumped 10.2% in today's pre-market trading after the company reported better-than-expected sales for its fourth quarter. The company added 13.12 million net paid subscribers in the fourth quarter of 2013. Getaround, Inc. Shares jumped 50.7% on Tuesday.
Benzinga · 01/24 13:14
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Getaround stock is rocketing more than 86% after securing $20 million in new financing. Evaxion Biotech shares are soaring over 41% alongside an investment from Merck. The biggest pre-market stock movers on Tuesday are the 10 top gainers and 10 top losers.
Investorplace · 01/24 12:37
Weekly Report: what happened at OPT last week (0115-0119)?
Weekly Report · 01/22 09:25
Weekly Report: what happened at OPT last week (0108-0112)?
Weekly Report · 01/15 09:24
More
Webull provides a variety of real-time OPT stock news. You can receive the latest news about Opthea Ltd through multiple platforms. This information may help you make smarter investment decisions.
About OPT
Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).